Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy

Int J STD AIDS. 2019 Oct;30(11):1042-1048. doi: 10.1177/0956462419848962. Epub 2019 Aug 20.

Affiliations

¹ Department of Internal Medicine and Infectious Diseases, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.
² Department of Internal Medicine and Endocrinology, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.
³ Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

PMID: 31431155
DOI: 10.1177/0956462419848962

No abstract available

Keywords: Dolutegravir; bone markers; inflammation markers; lipids; renal markers; tenofovir disoproxil fumarate.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antiretroviral Therapy, Highly Active*
Biomarkers / blood
Bone Density
Drug Therapy, Combination
Female
HIV Infections / drug therapy*
HIV Integrase Inhibitors / therapeutic use*
Heterocyclic Compounds, 3-Ring / therapeutic use*
Humans
Male
Middle Aged
Oxazines
Piperazines
Pyridones
Treatment Outcome

Substances

Biomarkers
HIV Integrase Inhibitors
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
dolutegravir